Alagebrium

DRUG3 trials

Sponsors

Synvista Therapeutics, Inc, Cardiovascular Clinical Sciences Inc

Conditions

Diabetes Mellitus, Type 1Diabetic NephropathyDiastolic Heart Failure

Phase 2

Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria

TerminatedNCT00557518

Synvista Therapeutics, IncDiabetes Mellitus, Type 1, Diabetic Nephropathy

Start: 2007-11-30End: 2009-11-30Target: 80Updated: 2009-01-30

Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)

TerminatedNCT00662116

Synvista Therapeutics, IncDiastolic Heart Failure

Start: 2008-03-31End: 2009-12-31Target: 160Updated: 2009-01-30

A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure

TerminatedNCT01913301

Cardiovascular Clinical Sciences IncDiastolic Heart Failure

Start: 2007-12-31End: 2009-05-31Updated: 2013-08-01